Status:
RECRUITING
Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment
Lead Sponsor:
Massimo Falconi
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to evaluate the financial toxicity reported by Italian patients affected by GEP-NEN during the first year of treatment after diagnosis and its correlations with patient-report...
Detailed Description
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are rare tumours whose incidence has increased during the years. However, referral centers specialized in diagnosis and treatment of these dis...
Eligibility Criteria
Inclusion
- ≥18 years of age
- New diagnosis of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN)
- Patients who are candidates for surgical and/or medical treatment \[including somatostatin analogues (SAA), peptide recector radionuclide therapy (PRRT), target therapies (everolimus or sunitinib) and chemotherapy\];
- Signed informed consent
Exclusion
- Age \< 18 years
- Patients diagnosed with GEP-NEN who are candidates for a surveillance management.
- Patients diagnosed with GEP-NEN who are candidates for best supportive care and/or have a life expectancy \< 6 months.
Key Trial Info
Start Date :
August 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 5 2024
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT05334290
Start Date
August 6 2020
End Date
August 5 2024
Last Update
March 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Ospedale San Raffaele
Milan, Italy, 20132